Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 RBC Capital Markets’ Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 10:20 a.m. E.D.T.
In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
ABOUT AURINIA
Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently developing the investigational drug voclosporin for the treatment of lupus nephritis, proteinuric kidney diseases, and dry eye syndrome. The Company’s head office is in Victoria, British Columbia and focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200515005546/en/
Aurinia Pharmaceuticals Inc. Aktie
Die Community ist bei Aurinia Pharmaceuticals Inc. noch unentschieden: Nur wenige Einschätzungen.
Das höhere Kursziel von 10 € im Vergleich zum aktuellen Kurs von 4.93 € für Aurinia Pharmaceuticals Inc. führt zu einem positiven Potenzial von 103.0%.